print Print    Share Share  


The Feminist Majority Foundation played a critical and decisive role in helping assure mifepristone's U.S. approval for safe and effective early medical abortion. In addition to fighting to expand women's safe abortion option, for more than a decade, the FMF has also been advocating for  non-abortion clinical trials using mifepristone to treat cancers and other life-threatening conditions that solely or disproportionately affect women.

Mifepristone, formerly known as RU-486, has anti-hormone properties. Early clinical trials have showed the drug's multiple medical potential. Access to the drug, however, was blocked for desperately ill patients and clinical trial development in general washeld up due to anti-abortion politics- until the FMF stepped in. 

The FMF took on the unusual responsibility of administering a "Mifepristone Compassionate Use" program in conjunction with the U.S. Food and Drug Administration (FDA) when no other scientific or medical professional organization would take on that perceived political risk. Today, we've assisted nearly 150 desperately ill patients with various kinds of ovarian cancers, brain tumors, breast cancers, endocrinopathies and psychiatric conditions access this drug that's been their only hope. We're thrilled that many patients have found this program to be a literal lifeline- the medication has worked and they've been on the program for years, even decades.

To forward mifepristone clinical trials on the myriad conditions that this drug may potentially treat, the FMF has put together a team of prestigious clincial researchers, attorneys, and FDA specialists, and has moved ahead wtih Phase II clinical trials for women with ovarian and uterine cancers.

Gender matters: If these conditions primarily affected men, the FMF suspects that a non-profit organization like ours wouldn't have to be working this hard to raise awareness about this healthcare inequity, administer the Compassionate Use Program, or raise money to help fund the clinical trials. But this is about women's cancers and we must break the logjam for this crucial research in addition to helping make this medication available to desperately ill patients on a Compassionate Use basis. We have an amazing opportunity to move forward: the reward may be to revolutionize the treatment of hormone-dependent female cancers.

When all else fails, feminists can make women's health research move forward.